Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

683 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Novel Family of Lysosomotropic Tetracyclic Compounds for Treating Leukemia.
Carbó JM, Cornet-Masana JM, Cuesta-Casanovas L, Delgado-Martínez J, Banús-Mulet A, Clément-Demange L, Serra C, Catena J, Llebaria A, Esteve J, Risueño RM. Carbó JM, et al. Among authors: esteve j. Cancers (Basel). 2023 Mar 22;15(6):1912. doi: 10.3390/cancers15061912. Cancers (Basel). 2023. PMID: 36980800 Free PMC article.
Applicability and validation of different prognostic scores in allogeneic hematopoietic cell transplant (HCT) in the post-transplant cyclophosphamide era.
Salas MQ, Rodríguez-Lobato LG, Charry P, Suárez-Lledó M, Pedraza A, Solano MT, Arcarons J, Cid J, Lozano M, Rosiñol L, Esteve J, Carreras E, Fernández-Avilés F, Martínez C, Rovira M. Salas MQ, et al. Among authors: esteve j. Hematol Transfus Cell Ther. 2024 Dec;46 Suppl 6(Suppl 6):S3-S12. doi: 10.1016/j.htct.2023.07.008. Epub 2023 Oct 12. Hematol Transfus Cell Ther. 2024. PMID: 37891074 Free PMC article.
Post-Transplantation Cyclophosphamide and Tacrolimus for Graft-versus-Host Disease Prevention after Allogeneic Hematopoietic Cell Transplantation from HLA-Matched Donors Has More Advantages Than Limitations.
Salas MQ, Pedraza A, Charry P, Suárez-Lledó M, Rodríguez-Lobato LG, Brusosa M, Solano MT, Serrahima A, Nomdedeu M, Cid J, Lozano M, Arcarons J, de Llobet N, Rosiñol L, Esteve J, Urbano-Ispizua Á, Carreras E, Fernández-Avilés F, Rovira M, Martinez C. Salas MQ, et al. Among authors: esteve j. Transplant Cell Ther. 2024 Feb;30(2):213.e1-213.e12. doi: 10.1016/j.jtct.2023.11.020. Epub 2023 Nov 30. Transplant Cell Ther. 2024. PMID: 38042256
Impact of letermovir prophylaxis in CMV reactivation and disease after allogenic hematopoietic cell transplantation: a real-world, observational study.
Brusosa M, Ruiz S, Monge I, Solano MT, Rosiñol L, Esteve J, Carreras E, Marcos MÁ, Riu G, Carcelero E, Martinez C, Fernández-Avilés F, Rovira M, Suárez-Lledó M, Salas MQ. Brusosa M, et al. Among authors: esteve j. Ann Hematol. 2024 Feb;103(2):609-621. doi: 10.1007/s00277-023-05542-6. Epub 2023 Nov 14. Ann Hematol. 2024. PMID: 37957371
Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML.
Jimenez-Chillon C, Othman J, Taussig D, Jimenez-Vicente C, Martinez-Roca A, Tiong IS, Jain M, Aries J, Cakmak S, Knapper S, Kristensen DT, Murthy V, Galani JZ, Kallmeyer C, Ngu L, Veale D, Bolam S, Orfali N, Parker A, Manson C, Parker J, Erblich T, Richardson D, Mokretar K, Potter N, Overgaard UM, Roug AS, Wei AH, Esteve J, Jädersten M, Russell N, Dillon R. Jimenez-Chillon C, et al. Among authors: esteve j. Blood Adv. 2024 Jan 23;8(2):343-352. doi: 10.1182/bloodadvances.2023011106. Blood Adv. 2024. PMID: 38039513 Free PMC article.
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.
Brunner AM, Esteve J, Porkka K, Knapper S, Traer E, Scholl S, Garcia-Manero G, Vey N, Wermke M, Janssen JJWM, Narayan R, Fleming S, Loo S, Tovar N, Kontro M, Ottmann OG, Naidu P, Sun H, Han M, White R, Zhang N, Mohammed A, Sabatos-Peyton CA, Steensma DP, Rinne ML, Borate UM, Wei AH. Brunner AM, et al. Among authors: esteve j. Am J Hematol. 2024 Feb;99(2):E32-E36. doi: 10.1002/ajh.27161. Epub 2023 Nov 22. Am J Hematol. 2024. PMID: 37994196 Clinical Trial.
Hypomethylating agents for patients with VEXAS without myelodysplastic syndrome: Clinical outcome and longitudinal follow-up of vacuolization and UBA1 clonal dynamics.
Álamo JR, Torres LM, Castaño-Díez S, Mensa-Vilaró A, Mónica López-Guerra M, Zugasti I, Díaz J, Jiménez-Vicente C, Plaza S, Fabregat V, de Landazuri IO, Yagüe J, Espinosa G, Sanmartí R, Rozman M, Guijarro F, Cortes A, Triguero A, Cardús A, Cuartas A, Cornejo M, Esteve J, Aróstegui JI, Díaz-Beyá M. Álamo JR, et al. Among authors: esteve j. Br J Haematol. 2025 Jan 13. doi: 10.1111/bjh.19953. Online ahead of print. Br J Haematol. 2025. PMID: 39806534
683 results